BIOADAPTIVES, INC.
For the period ended Dec 31, 2024. Filed Apr 15, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 15, 2025
BDPTStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheet
CONSOLIDATED BALANCE SHEETS
| December 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current Assets: | ||
| Cash | $137,470 | $60,776 |
| Inventory | 19,115 | 15,281 |
| Security deposit | 2,500 | 2,500 |
| Prepaid expense | 100,000 | 10,000 |
| Other receivable | 2,800 | - |
| Total Current Assets | 261,885 | 88,557 |
| License and patent, net | - | 15,441 |
| TOTAL ASSETS | $261,885 | $103,998 |
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||
| Current Liabilities: | ||
| Accounts payable and accrued liabilities | 179,428 | 443,579 |
| Derivative liabilities | 1,053,249 | 977,872 |
| Convertible notes - net of discount of $0 and $52,592 | 311,000 | 321,658 |
| Notes Payable | 32,096 | - |
| Note payable - related party | 7,520 | |
| Stock Payable | 150,000 | - |
| Total Current Liabilities | 1,725,803 | 1,750,629 |
| Total Liabilities | 1,725,803 | 1,750,629 |
| Stockholders’ Deficit: | ||
| Preferred stock, ($0.0001 par value, 10,000,000 shares authorized; | ||
| Series A Preferred Stock 4,000,000 shares designated; 11,167 and 9,500 issued and outstanding as of December 31, 2024 and December 31, 2023, respectively | 1 | 1 |
| Series B Preferred Stock 5,000,000 shares designated; 9,667 and 7,500 share issued and outstanding as of December 31, 2024 and December 31, 2023, respectively | 1 | 1 |
| Series C Preferred Stock 1,000,000 shares designated; 1,000,000 and 0 share issued and outstanding as of December 31, 2024 and December 31, 2023, respectively | 100 | - |
| Series D Preferred Stock 20,000,000 shares designated; 72,687 and 0 share issued and outstanding as of December 31, 2024 and December 31, 2023, respectively | 7 | - |
| Common stock ($0.0001 par value, 1,250,000,000 shares authorized; 8,215,426 and 5,971,728 shares issued and outstanding as of December 31, 2024 and December 31, 2023, and 66 issuable, respectively) | 821 | 597 |
| Additional paid-in capital | 7,704,343 | 6,616,915 |
| Subscription receivable | (5,885) | - |
| Accumulated deficit | (9,163,306) | (8,264,145) |
| Total Stockholders’ Deficit | (1,463,918) | (1,646,631) |
| TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT | $261,885 | $103,998 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.